Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Withdrawn 2Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Recurrence 1Optic Neuritis 1Neuromyelitis Optica 1Myelitis, Transverse 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Interventional × LFB-R603 × Clear all
NCT03804996 2024-04-08

Study of TG-1801 in Subjects With B-Cell Lymphoma

TG Therapeutics, Inc.

Phase 1 Completed
50 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT01098188 2012-04-30

LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia

Laboratoire français de Fractionnement et de Biotechnologies

Phase 1 Completed
33 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡